All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stephanie Noviello, Jeong Heo et al.|The Lancet|2014Cited by 343
O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTSM.P. Manns, Stephanie Noviello, S. Pol et al.|Journal of Hepatology|2014Cited by 20
Daclatasvir plus asunaprevir for <scp>HCV</scp> genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia‐Horng Kao, Stephanie Noviello, Donald M. Jensen et al.|Liver International|2015Cited by 16
P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDYJia‐Horng Kao, M.P. Manns, June Heo et al.|Journal of Hepatology|2014Cited by 9